A team led by Christian Baumgartner of the Institute of Health Care Engineering at Graz University of Technology (TU Graz) ...

The RESOLUTE phase III trial of AstraZeneca’s Fasenra (benralizumab), despite showing numerical improvement, did not achieve statistical significance in the primary endpoint in patients with chronic ...

Regular physical activity reduces the risk of chronic obstructive pulmonary disease (COPD)1 and improves the prognosis in affected patients.2 In contrast, ambient air pollution, is a substantial risk ...

A new study reveals that small cell lung cancer (SCLC) likely begins in basal stem-like cells rather than in neuroendocrine ...

AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and ...

AstraZeneca ( NASDAQ: AZN) said that the late-stage trial for its medication Fasenra (benralizumab) in patients suffering ...

Dr. Ross Camidge has helped treat thousands of lung cancer patients. Now, in a crazy life twist, Camidge is a lung cancer patient himself.

Topline data were announced from a phase 3 trial evaluating efzofitimod in patients with pulmonary sarcoidosis.

AstraZeneca (AZN) announced on Wednesday that its late-stage trial of Fasenra in patients with chronic obstructive pulmonary ...

Privately-held Areteia Therapeutics has announced positive results from the Phase III EXHALE-4 efficacy and safety study of ...

Researchers explore innovative macrocyclic peptides to target small cell lung cancer, revealing promising therapeutic ...

Dexpramipexole was well tolerated, and had a favorable safety profile.